Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Cardiovascular, Case Report
Cardiovascular, Editorial
Cardiovascular, Images in Cardiology
Cardiovascular, Interventional Round
Cardiovascular, Original Article
Cardiovascular, Preface
Cardiovascular, Review Article
Cardiovascular, Student’s Corner
Case Report
Case Reports
Clinical Discussion
Clinical Rounds
CPC
Debate
Dedication
Editorial
Expert Comments
Expert's Opinion
Genetic Autopsy
Genetics Autopsy
Image in Cardiology
Images in Cardiology
Interventional Round
Interventional Rounds
Letter to the Editor
Media and news
Original Article
Practice in Medicine
Preface
Review Article
Scientific Paper
Short Communication
Student's Corner
WINCARS Activities
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Cardiovascular, Case Report
Cardiovascular, Editorial
Cardiovascular, Images in Cardiology
Cardiovascular, Interventional Round
Cardiovascular, Original Article
Cardiovascular, Preface
Cardiovascular, Review Article
Cardiovascular, Student’s Corner
Case Report
Case Reports
Clinical Discussion
Clinical Rounds
CPC
Debate
Dedication
Editorial
Expert Comments
Expert's Opinion
Genetic Autopsy
Genetics Autopsy
Image in Cardiology
Images in Cardiology
Interventional Round
Interventional Rounds
Letter to the Editor
Media and news
Original Article
Practice in Medicine
Preface
Review Article
Scientific Paper
Short Communication
Student's Corner
WINCARS Activities
View/Download PDF

Translate this page into:

Editorial
5 (
02
); 109-110
doi:
10.1055/s-0040-1713949

Cardiovascular Comorbidities in Women with Psoriasis

Department of Dermatology, DERMACARE, Hyderabad, India
Address for correspondence Durga Prasad Annabathula, MBBS, DD Department of Dermatology, DERMACARE Hyderabad, 500047 India dp@dermacareindia.com
Licence
This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Disclaimer:
This article was originally published by Thieme Medical and Scientific Publishers Private Ltd. and was migrated to Scientific Scholar after the change of Publisher; therefore Scientific Scholar has no control over the quality or content of this article.

The prevalence of cardiovascular (CV) risk factors among psoriasis patients is well-known, and therefore there is an elevated risk of CV disease (CVD). Psoriasis is associated with an elevated risk of myocardial infarction, stroke, and also death caused by CVD, which are as a whole referred to as major adverse cardiovascular events (MACE).1 It also has been detailed that the magnitude of these risk factors is directly proportionate to the severity of psoriasis.1

Atherosclerosis, which is a chronic inflammatory disease of the blood vessels, is usually the cause for CVD. Atherosclerosis is associated with both innate and adaptive immune responses that involve the Th-1 and Th-17 pathways.2 3 On the other hand, psoriasis is also a chronic inflammatory disorder which displays its association with Th-1 and Th-17 mediated inflammation, resulting in production of IL-17, INF-gamma and TNF and leading to the formation of plaques over the skin. This similarity in the immunological and inflammatory pathways implies a relationship between CVD and psoriasis.3 4

The various determinants of CVD evaluated in this study5 were elevated waist circumference (> 80 cm), raised triglycerides (> 150 mg/dL), reduced high-density lipoprotein (HDL) (< 50), fasting blood glucose (> 100 mg/dL), and raised blood pressure which constitute the metabolic syndrome, high-sensitivity C-reactive protein (hsCRP), weight and carotid intima media thickness (CIMT). The various other variables (related to psoriasis) that were recorded in this study5 are the duration of psoriasis, family history of the same, intake of drugs that trigger psoriasis, and the severity of the disease which was assessed by Psoriasis Area Severity Index (PASI) and body surface area (BSA). The other quality scoring systems of psoriasis that are methodologically validated are PGA (Physician’s Global Assessment)/IGA mod 2011 (Investigator’s Global Assessment modified in 2011), LS-PGA (Lattice System-Physician’s Global Assessment, and SPI (Salford psoriasis index).6 These assessment tools have, however, not been used in this study5 to assess the severity of the disease which can be considered as a demerit of the study.5

The incidence of metabolic syndrome in women was found to be higher than in men, owing to the preponderance of women to develop central obesity (increased waist circumference).7 Also, inflammation increases the degree of occurrence of metabolic syndrome, particularly in women, which, in turn, elevates the CV risk.8 Given that psoriasis is a chronic inflammatory disease, it poses a greater risk of CVD in women.9 This study5 showed higher prevalence of metabolic syndrome in cases with psoriasis than in controls, which is in accordance with the research conducted by Regitz-Zagrosek et al.8 9

It has been concluded in a study done by Pietrzak et al10 that the relation of CVD and psoriasis in females intensifies with age. However, no such associations have been recorded in this study.5

It is demonstrated by this study5 that hsCRP, which is an important indicator of atherosclerosis, was raised in patients with psoriasis, in close agreement with the study carried out by Jindal et al.4 It was also stated by this study5 that CIMT, which is a salient tool for the measurement of subclinical atherosclerotic changes, was elevated among psoriasis cases than in controls which is, again, in conformity with Jindal et al.4

All the other determinants of CVD evaluated in this study5 had higher incidence in women with psoriasis than in women without psoriasis, which is in correspondence with Jindal et al.4

Therefore, it is of utmost importance that the female patients with psoriasis be orderly screened for the various CV risk factors for early detection and prevention of CVD.

Conflict of Interest

None declared.

References

  1. , , , et al . Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017;76(03):377-390.
    [Google Scholar]
  2. , , . The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6(07):508-519.
    [Google Scholar]
  3. , , , et al . Prevalence and extent of subclinical atherosclerosis in patients with psoriasis. J Intern Med. 2013;273(03):273-282.
    [Google Scholar]
  4. , , . Psoriasis and cardiovascular diseases: a literature review to determine the causal relationship. Cureus. 2018;10(02):e2195.
    [Google Scholar]
  5. , , , et al . Determinants of cardiovascular disease among urban women with psoriasis: a case–control study. 2020
    [CrossRef] [Google Scholar]
  6. , , , et al . What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24:10-16.
    [Google Scholar]
  7. , , . Prevalence of metabolic syndrome and gender differences. Bioinformation. 2012;8(13):613-616.
    [Google Scholar]
  8. , , , . Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol. 2006;95(03):136-147.
    [Google Scholar]
  9. , , , . Skin disease related to metabolic syndrome in women. Int J Womens Dermatol. 2019;5(04):205-212.
    [Google Scholar]
  10. , , , et al . Cardiovascular disease in psoriatic post-menopausal women. J Eur Acad Dermatol Venereol. 2015;29(06):1231-1234.
    [Google Scholar]

Fulltext Views
7

PDF downloads
0
View/Download PDF
Download Citations
BibTeX
RIS
Show Sections